首页> 美国卫生研究院文献>Acta Crystallographica Section F: Structural Biology and Crystallization Communications >Structure of the SH3 domain of human osteoclast-stimulating factor at atomic resolution
【2h】

Structure of the SH3 domain of human osteoclast-stimulating factor at atomic resolution

机译:人破骨细胞刺激因子SH3结构域的原子分辨率。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Osteoclast-stimulating factor (OSF) is an intracellular signaling protein, produced by osteoclasts themselves, that enhances osteoclast formation and bone resorption. It is thought to act via an Src-related signaling pathway and contains SH3 and ankyrin-repeat domains which are involved in protein–protein interactions. As part of a structure-based anti-bone-loss drug-design program, the atomic resolution X-ray structure of the recombinant human OSF SH3 domain (hOSF-SH3) has been determined. The domain, residues 12–72, yielded crystals that diffracted to the ultrahigh resolution of 1.07 Å. The overall structure shows a characteristic SH3 fold consisting of two perpendicular β-­sheets that form a β-barrel. Structure-based sequence alignment reveals that the putative proline-rich peptide-binding site of hOSF-SH3 consists of (i) residues that are highly conserved in the SH3-domain family, including residues Tyr21, Phe23, Trp49, Pro62, Asn64 and Tyr65, and (ii) residues that are less conserved and/or even specific to hOSF, including Thr22, Arg26, Thr27, Glu30, Asp46, Thr47, Asn48 and Leu60, which might be key to designing specific inhibitors for hOSF to fight osteoporosis and related bone-loss diseases. There are a total of 13 well defined water molecules forming hydrogen bonds with the above residues in and around the peptide-binding pocket. Some of those water molecules might be important for drug-design approaches. The hOSF-SH3 structure at atomic resolution provides an accurate framework for structure-based design of its inhibitors.
机译:破骨细胞刺激因子(OSF)是破骨细胞自身产生的一种细胞内信号蛋白,可增强破骨细胞的形成和骨吸收。它被认为是通过Src相关的信号通路起作用的,并包含SH3和锚蛋白重复域,它们参与蛋白质间相互作用。作为基于结构的抗骨丢失药物设计程序的一部分,已确定了重组人OSF SH3域(hOSF-SH3)的原子分辨率X射线结构。该区域,残基12-72,产生的晶体衍射至1.07Å的超高分辨率。整体结构显示出特征性的SH3折叠,由两个垂直的β-β片组成,形成β-桶。基于结构的序列比对揭示,hOSF-SH3的假定的富含脯氨酸的肽结合位点由(i)在SH3-结构域家族中高度保守的残基组成,包括残基Tyr21,Phe23,Trp49,Pro62,Asn64和Tyr65 (ii)对hOSF保守性和/或特异性更低的残基,包括Thr22,Arg26,Thr27,Glu30,Asp46,Thr47,Asn48和Leu60,这可能是设计hOSF特异性抑制剂与骨质疏松症及相关疾病的关键骨质流失疾病。在肽结合袋内和周围,共有13个定义良好的水分子与上述残基形成氢键。这些水分子中的某些对于药物设计方法可能很重要。 hOSF-SH3原子分辨率的结构为其抑制剂的基于结构的设计提供了准确的框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号